Overexpression and Mutation of p53 in Epithelial Ovarian Cancer

Cancer Research

Volumn 51, Issue 11, 1991, Pages 2979-2984

  Marks, J R ^a,e   Berchuck, A ^c   Pence, J C ^a   Iglehart, J D ^a  

^a Departments of Surger ^*  (United States)

^b Pathology ^*  (United States)

^c Biostatistics ^*  (United States)

^d Obstetrics and Gynecology/Gynecologic Oncology ^*  (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENES, P53; HUMAN; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLOIDIES;

EID: 0025743791     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rogel, A., Popliker, M., Webb, C. G., et al. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol., 5:2851-2855, 1985.
2. Takahashi, T., A'au, M. M., Chiba, I., et al. p53: A frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246:491-494, 1989.
3. Migro, J. M., Baker, S. J., Preisinger, A. C., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-708, 1989.
4. Prosser, J., Thompson, A. M., Cranston, G., et al. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene, 5: 1573-1579. 1990.
5. Soussi, T., deFromentel, C. C. Mediali, M., et al. Cloning and characteriza tion of a cDNA from Xenopus aeviscoding for a protein homologous to human and murine p53. Oncogene, 1: 71-78, 1987.
6. Finlay, C. A., Hinds, P. W., Tan, T-H., et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-line. Mol. Cell. Biol., 8: 531-539, 1988.
7. Parada, L. F., Land, H., Weinberg, R. A., et al. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (Lond.), 312: 649-651, 1984.
8. Eliyahu, D., Raz. A., Gruss, P., et al. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (Lond.), 312: 646-649, 1984.
9. Jenkins, J. R., Kudge. K., C'humakov, P., et al. The cellular oncogene p53 can be activated by mutagenesis. Nature (Lond.). 317: 816-818, 1985.
10. Hinds. P., Finlay. C., and Levine. A. J. Mutation is required to activate the pS3 gene for cooperation with the ras oncogene and transformation. J. Virol. 63: 739-746, 1989.
11. Kraiss, S., Quaiser, A., Oren, M., et al. Oligomerization of oncoprotein p53. J. Virol., 62: 4737-4744, 1988.
12. Green, M. R. When the products of oncogenes and antioncogenes meet. Cell, 56: 1-3, 1989.
13. Finlay, C. A., Hinds. P. W. and Levine. A. J. The p53 protooncogene can act asa suppressor of transformation. Cell, 57: 1083-1093. 1989.
14. Hahn D., Michalovitz. D., Eliyahu. S., et al. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Nati. Acad. Sci. 46: 8763-8767. 1989.
15. Baker, S. J., Markowitz, S., Fearon. E. R., et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915. 1990.
16. Bcrchuck. A., Kamel. A., Whitaker. R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 14: 4087-4091. 1990.
17. Slamon, D. J., Godolphin. W., Jones, L. A., et al. Studies of HER-2/ncu protooncogene in human breast and ovarian cancer. Science (Washington DC) 244:101-112, 1989.
18. Eccles, D. M., Cranston, G., Steel, C. M., etal. Alaelelosses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene. 5: 1599-1601. 1990.
19. Russell. S. E. H., Mickey. G. I., Lowry. W. S., et al. Alaeleloss from chromosome 17 in ovarian cancer. Oncogene, 5: 1581-1583, 1990.
20. Annual Report on the Treatment of Gynecologic Cancer. In: H. L. Kottmeier (ed.). International Federation of Gynecologists and Obstetricians Stock holm, Sweden. Vol. 17, 1979.
21. Serov, S. F., and Scully. R. E. Histological typing of ovarian tumors. In: International Histological Classification of Tumors, No. 9. Geneva: World Health Organization. 1973.
22. Banks. L., Matlashewski. G., and Crawford, L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159: 529-534, 1986.
23. Wade-Evans, A., and Jenkins. J. R. Precise epitope mapping of the murine transformation-associated protein. p53. F.MBO J., 4: 699-706. 1985.
24. Gannon. J. V., Greaves. R., Iggo. R., et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
25. Bartek, J., Iggo, R., Gannon, J., et al. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-899. 1990.
26. Gerdes. J., Lemke. H., Baisch. H., et al. Cell cycle analysis of a cell prolif eration-associated human nuclear antigen defined by a monoclonal antibody. J. Immunul. 133: 1710-1715. 1984.
27. Chomczynski. P., and Sacchi. N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159. 1987.
28. Saiki. R. K., Gelfand. D. H., Stoffel. S., et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (Washington DC). 239:487-491. 1988.
29. Kaplan. E. L., and Meier. P. Nonparametric estimation from incomplete observations. J. Am. Slat. Assoc. 53: 457-481. 1958.
30. Mantel. N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50: 163-170. 1966.
31. Davidoff. A. M., Humphrey. P. A., Iglehart. J. D., et al. Genetic basis p53 overexpression in human breast cancer. Proc. Nati. Acad. Sci., in press. 1991.
32. Lamb. P., and Crawford. L. Characterization of the human p53 gene. Mol. Cell. Biol., 6: 1379-1385, 1986.
33. Iggo. R., Gatter, K., Bartek. J., et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335: 675-679. 1990.
34. Lavigueur. A., Maltby. V., Mock, D., et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alaelesof the p53 oncogene. Mol. Cell. Biol. 9: 3982-3991. 1989.
35. Malkin, D., Li. F. P., Strong. L. C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC). 250: 1233-1238. 1990.